During a roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Forsberg Explains How Selinexor Fits Into Sequencing Therapies in R/R Multiple Myeloma
Default sub title
minute read
by Targeted Oncology | November 16, 2022
